AstraZeneca doubles down on hot cancer target, paying $63M for ADC months after bispecific deal
https://www.fiercebiotech.com/biotech/astrazeneca-doubles-down-hot-cancer-target-paying-63m-adc-months-after-bispecific-deal
Medical Innovation Exchange @ Copywrite 2021. All Rights Reserved.